Justin Quinn

An early contributor to the platforms of a number of biotech startups, including Moderna and TCR2 therapeutics. Most recently, he was at the forefront in the battle against SARS-CoV-2 with the development of next-gen vaccine technologies, but as an original member of the woolly mammoth de-extinction team at the Church lab, he has re-focused his efforts to revive extinct species and restore ecosystems. As the Director of Product Research, he is responsible for turning obstacles into innovation opportunities, and de-extinction technologies into platforms at Colossal Biosciences.

We have recently structured a research collaboration agreement with Dr. Paul Ling, foremost expert on elephant endotheliotropic herpes virus (EEHV) out of Baylor College of Medicine, to explore the elephant immune response to EEHV and leverage the genomic insights to develop novel immune interventions that can improve elephant conservation efforts and equip modern elephants and mammoths with a potent immune defense.